Analysts Set Haleon plc (LON:HLN) PT at GBX 395.67

Haleon plc (LON:HLN) has been assigned an average recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is GBX 399.

A number of research analysts have weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 400 target price on shares of Haleon in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft raised their price target on shares of Haleon from GBX 325 to GBX 335 and gave the stock a “sell” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. dropped their price objective on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research note on Thursday, June 25th. Berenberg Bank upped their price objective on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada increased their price objective on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a report on Tuesday.

Haleon Trading Down 1.5%

Shares of Haleon stock opened at GBX 359.90 on Monday. The firm has a market cap of £31.70 billion, a PE ratio of 19.88, a P/E/G ratio of 1.49 and a beta of 0.24. Haleon has a 1 year low of GBX 317.80 and a 1 year high of GBX 416.10. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. The stock has a fifty day moving average price of GBX 354.57 and a 200-day moving average price of GBX 362.90.

Haleon (LON:HLN) last posted its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 15.11% and a return on equity of 10.30%. Equities research analysts anticipate that Haleon will post 19.5033282 EPS for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.